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CE Mark approval in September 2011 and to date over 100 commercial implants have been
performed. The device is composed of a porcine biologic valve attached to a self-expanding
nitinol stent designed for simple 2-step implantation and characterized by controlled position-
ing, self-seating in the native annulus resulting in a negligible paravalvular leak rate. The
device was tested in patients at high-risk for mortality with open surgical repair.
Methods: Ninety (90) patients (female69%) with severe aortic stenosis, a mean age of
83.4  4.1 years, all presenting with NYHA Functional Class III or IV and a mean STS
Score of 7.9  4.6 were enrolled in two studies in Germany at 6 centers. Patients are
clinically followed at 7 and 30 days, at 6 and 12 months, and annually thereafter out to
5 years post-implant. The device was successfully implanted in 94.4% of patients (n85)
with a pacemaker implantation rate of 11.1% (n10).
Results: At 12 months the survival rate is 81.1% (n73), the stroke rate is 4.4% (n4),
with no further re-intervention required on the implanted device since procedure. Of the
returning patients, 87% presented with NYHA Functional Class I/II. The mean gradient
at 6 months is 10.3 5.2 mmHg, the mean EOA is 1.5 0.4 cm2 and 77.3% of returning
patients suffered no paravalvular leak, 21.2% exhibit mild paravalvular leak (	1) and only
1 patient possesses a moderate paravalvular leak (	2).
Conclusions: These data confirm the safety profile at one year of this 2nd Generation
TAVI system. We will report the full 12 months results of this multi-center, non-
randomized study of this transapically-placed transcatheter aortic valve at TCT 2012.
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Background: Transcatheter aortic valve implantation (TAVI) has emerged as an
accepted treatment alternative for high risk patients with severe aortic stenosis. This study
was designed to evaluate the safety and efficacy of transapical aortic valve implantation
in high risk patients using the second generation JenaValve TAVI system. It consists of
a biological porcine valve mounted on a self-expanding Nitinol stent. Retrieval capability,
feeler guided anatomically positioning and clipping fixation on the diseased leaflets
provide potential advantages compared to current TAVI systems.
Methods: This study enrolled a total of 73 patients of whom 67 patients (mean age 83.13.9;
Euroscore 28.46.5) underwent elective TAVI at 7 German centers. Primary endpoint was all
cause mortality at 30 days. Procedural success, major adverse cerebrovascular and cardiac
events, functional improvement and echocardiographic valve performance were assessed at
baseline, post-procedure, discharge, 30 day, 3, 6, and 12 months.
Results: 60 of 67 patients underwent successful TAVI with the JenaValve resulting in a
procedural success of 89.6%. Pacemaker implantation for new onset conduction disorders
was necessary in 6 patients (9.1%). No coronary ostium obstructions were seen. TAVI
resulted in favorable reduction of mean transvalvular gradients (40.016.1mmHg vs.
10.07.3mmHg, p 0.0001) and increase in valve opening area (0.70.2cm2 vs.
1.70.6cm2, p 0.0001). None of the successful implanted patients had severe post
procedural aortic regurgitation ( grade 2). Survival at 30 days and 6 months was 92.4%
and 74.3% respectively. Stroke occurred in 4 patients (6.0%) at 6 months. NYHA Class
improved significantly at 6 months after valve implantation (5.4% NYHA class I, 56.8%
NYHA class II and 37.8% with class III). 12 months outcomes will be presented
according to VARC criteria at the conference.
Conclusions: TAVI using the JenaValve system has proven to be an effective treatment
option in high risk patients with aortic stenosis with good short and mid-term outcome.
Anatomically correct positioning and clip-fixation of the native leaflet led to good
hemodynamic function and favorably reduced paravalvular leak rates.
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Background: The Edwards SAPIEN valve has been FDA-approved with its Retroflex
delivery system for retrograde transfemoral (TF) treatment of inoperable patients with
severe aortic stenosis, and is the only device clinically available for transcatheter aortic
valve replacement (TAVR) in the United States (US). Because of insufficient iliofemoral
vascular access, many patients are excluded from the TF approach. We explored
transaortic (TAO) TAVR as an alternate access strategy for these patients.
Methods: Twenty-five consecutive patients underwent TAO TAVR between January
and April, 2012 at our site. All had symptomatic severe aortic stenosis, were inoperable,
and had inadequate vascular access for TF delivery. Through a small upper sternotomy
and direct insertion of the sheath into the ascending aorta, we delivered the valve using the
Retroflex catheter. Procedural and 30-day outcomes were retrospectively compared with
the first 25 patients treated by transapical (TA) access in our program.
Results: TAO TAVR was successfully performed in all patients. One perioperative death
occurred, which was unrelated to the TAO approach. No other cardiovascular death was
reported within 30 days. Compared with TA access, TAO TAVR had a similar all-cause
mortality rate at 30 days, and was associated lower incidence of bleeding events, as well
as shorter ICU length of stay.
BASELINE DEMOGRAPHICS
Trans-Aortic
Series
Trans-Apical
Series P-Value
Median Age (Years 	/SD) 83 (	/5) 85 (	/6) 0.35
Male Gender 10 (40%) 15 (60%) 0.26
Median STS Score (	/SD) 8 (	/4.4) 10.8 (	/3.27) 0.009
Operable for conventional
AVR
0% 100% 0.00
NYHA Class 3 & 4 24 (96%) 25 (100%) 1.00
Median AVA (cm2) 0.62 (	/0.15) 0.60 (	/0.12) 0.62
Median LVEF (%) 60 (	/16) 50 (	/15) 0.38
PROCEDURAL OUTCOMES*
Implantation Success 25 (100%) 25 (100%) 1.00
Moderate or Severe AI or PVL 1 (4%) 4 (16%) 0.35
Emergency open surgery 1 (4%) 1 (4%) 1.00
Procedural Mortality 1 (4%) 0 (0%) 1.00
30-DAY OUTCOMES*
Cardiovascular Mortality 1 (4%) 3 (12%) 0.61
All-Cause Mortality ** 5 (20%) 4 (16%) 1.00
Median ICU Length of Stay 3.0 (	/3.4) 6.0 (	/9.5) 0.013
Median Hospital Length of
Stay
7.0 (	/6.6) 11.0 (	/9.0) 0.069
Myocardial Infarction 0 (0%) 0 (0%) 1.00
Major Stroke 0 (0%) 1 (4%) 1.00
Minor Stroke 1 (4%) 0 (0%) 1.00
Major/Disabling Bleeding 3 (12%) 10 (40%) 0.05
Vascular Access
Complications
2 (8%) 2 (8%) 1.00
Acute Kidney Injury Stage 3 1 (4%) 0 (0%) 1.00
* Adjudicated using VARC criteria.
** 3 pneumonia-related respiratory failure, 1 C. difficile sepsis, 1 procedural death.
Conclusions: TAVR via the TAO approach, using the only commercially-available
device in the US, is technically feasible and is associated with favorable outcomes in
inoperable patients with severe aortic stenosis who are not candidates for TF access. In
these patients, the TAO approach expands the current alternative options for TAVR
access sites. Efforts directed towards enhancing the technologies and techniques associ-
ated with TAO TAVR should further improve the efficacy and safety of this procedure.
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Background: Transcatheter aortic valve replacement is recommended in inoperable
patients with severe, symptomatic aortic stenosis (AS), and is an accepted alternative to
surgical AVR in high risk patients. However, increased stroke, bleeding, vascular
complications and aortic regurgitation (AR) rates may adversely affect outcomes. The
repositionable and fully retrievable Lotus Valve is designed to facilitate accurate
positioning and minimize paravalvular leakage.
Methods: REPRISE I is a prospective, single-arm, 3-center feasibility study to assess
acute safety and performance in symptomatic patients with severe AS at high surgical risk.
The primary endpoint was clinical procedural success (successful implantation without
in-hospital major adverse cardiovascular and cerebrovascular events to discharge or 7
days, whichever came first).
Results: The Lotus Valve was implanted in 11 patients with mean STS and logistic
euroSCOREs of 4.92.5% and 9.54.4%, respectively, and high surgical risk due to
comorbidities/frailty (cognitive dysfunction in 5/11, gait speed 6s in 9/11, grip strength
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